The article examines the objective, findings, and clinical context described in Anticoagulant recalled over life-threatening risk.
Approach:
Recall scope: The recall covers 22 lots of argatroban injection, 250 mg/2.5 mL (100 mg/mL), distributed under the Par Health and Endo USA names. It applies to two NDCs: 42023-182-01 (20 lots) and 42023-182-89 (2 lots).
Contamination and risks: Particles identified included cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel. The company warned that use could cause serious vascular complications.
Distribution and response: Affected lots were distributed to US wholesalers and hospitals from December 30, 2024, through May 5, 2026. Distributors and hospital pharmacies should stop use and distribution, and notify downstream recipients if products were redistributed.
Key Findings:
Potential complications include pulmonary emboli, occlusion of other blood vessels that may cause tissue death or organ damage, and venous-wall inflammation that may lead to clot formation.
As of the company’s October 13 announcement, no adverse events associated with the recalled products had been reported.
The recall is limited to the specified lots; it does not cover all argatroban injection products.
Interpretation:
Par Health described the contamination as presenting a reasonable probability of serious adverse health consequences. The FDA published the company’s recall announcement on October 14, 2026.
Limitations:
The context does not provide the individual lot numbers or quantities recalled.
No adverse events had been reported as of October 13; the context does not provide later safety information.
Conclusion:
Argatroban is indicated for prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT), and for anticoagulation in adults with or at risk for HIT undergoing percutaneous coronary intervention. Product-return questions can be directed to Inmar at 1-855-648-7909 or rxrecalls@inmar.com; medical or technical inquiries and product complaints can be directed to Par Health at 1-800-828-9393.
